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0.431(HAMD-17), -0.224(PCS), -0.650(MCS) -all p0.001-. Differences in CUDOS
scores between severity levels were found (p0.03-Bonferroni correction-). The
ability of CUDOS for predicting remission was adequate (AUC 0.837; CI 0.740-
0.934; p0.001. A cut-off point (CUDOS 24) was estimated (sensitivity0.81, spec-
ificity 0.77). CONCLUSIONS: The Spanish version of the CUDOS is a reliable and
valid measure of depression which can detect MDD patients with a suboptimal
response and be easily used during clinical practice in Primary Care.
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OBJECTIVES: To identify symptoms and functional impacts associated with major
depressive disorder (MDD) using concept elicitation interviews with patients to
determine relevant concepts for assessment in patient-reported outcome (PRO)
measures.METHODS:Qualitative interviews were conducted at 6 U.S. clinical sites
for cross-sectional assessment in a sample of adults (18-65 years) meeting DSM-
IV-TR criteria for MDD with a depressive episode within the last 6 months and
HAM-D score 18 at screening. Semi-structured individual interviews conducted
by trained research staff used open-ended questions and day-reconstruction exer-
cises to elicit spontaneous reports of symptom/impact concepts. Subsequent prob-
ing was used to assess concepts not spontaneously reported by subjects. Inter-
views were audio-recorded and transcribed. Transcripts were coded and analyzed
using Atlas.ti and summarized by like-content. Interview guide notations were
used to tag concepts offered by either spontaneous or probed report. RESULTS: A
total of 40 interviews were conducted with subjects (mean age: 46.211.8; 67.5%
female) representing a broad range of demographic characteristics. Saturation of
concepts was achieved within the first 32 interviews. Symptoms identified by the
majority of subjects included: Sadness (80.0% of subjects overall [and 52.5% spon-
taneously]), Tiredness (75.0[65.0]), Anger (72.5[57.5]), Loneliness (70.0[45.0]), Diffi-
culty Falling Asleep (67.5[55.0]), Low Self-Esteem (65.0[32.5]), Anxiety (62.5[55.0]),
Guilt (62.5[42.5]), Trouble Focusing (60.0[42.5]), Difficulty Waking (60.0[35.0]), Fa-
tigue (57.5[50.0]) and Irritability (57.5[42.5]). The most frequently reported impacts
were: Having Fewer Friends (92.5[65.0]), Feeling Isolated (82.5[57.5]), Dropping Daily
Activities (82.5[55.0]), Difficulty with Chores (77.5[30.0]), Interpersonal Difficulties
(72.5[37.5]), Workplace Difficulties (65.0[52.5]) and Neglecting Self-Hygiene
(65.0[17.5]). CONCLUSIONS: Symptoms and functional impacts associated with
MDD were identified through qualitative interviews. Relevant patient-identified
concepts should be considered in the development of patient-reported outcomes.
Concepts reported spontaneously provide good support for relevance, whereas
other concepts identified primarily through probing may not offer the best candi-
dates for assessment. Strength of these findings is suggested by achievement of
concept saturation.
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OBJECTIVES: To identify ways patients describe Major Depressive Disorder (MDD)
symptoms and impacts so new patient-reported outcome (PRO) measures can ef-
fectively incorporate the patient’s voice and perspective. METHODS: Qualitative
interviews were conducted with adult MDD patients (18-65 years) recruited from 6
US clinical sites. Patients were required at screening to have a Hamilton Depression
Rating Scale (HAM-D) score of18 and suffer depression within the past 6 months.
Individual interviews conducted by trained researchers used a semi-structured
interview guide designed to elicit responses about MDD symptoms and related
impacts. Interviews were audio-recorded, transcribed, cataloged and organized
into a coding framework using Atlas.ti software for content analysis. RESULTS:
Forty interviews were conducted. Mean age of participants was 46.2 (SD11.8);
67.5% were female, and 45.0% described their race as white. Saturation of concepts
was achieved within the first 32 interviews. A total of 3022 symptom and 830
impact code stems were derived from the transcripts. Eleven different domains
were developed in the coding framework for symptoms. Domains with the greatest
number of symptom expressions included Emotions/Mood (624/3022 [20.6%] of
expressions), Anxiety (398/3022 [13.2%]), and Cognition (358/3022 [11.8%]). Four dif-
ferent impact domains were identified, with Difficulty with Daily Activities (340/
830 [41.0%]) and Social/Relationship Changes (319/830 [38.4%]) receiving the great-
est number of expressions. A variety of different descriptions were used to
communicate these domains and sub-domains; representative quotations will be
presented. CONCLUSIONS: A broad range of concepts and terminology is used by
patients to describe the symptoms and impacts associated with their depression.
Participants identified symptoms that included both expected (based on diagnostic
criteria) and those not commonly described as core symptoms of MDD. Organiza-
tion of quotations into a coding framework and dictionary allows for the selection
of concepts and incorporation of the most meaningful patient language into early
stages of PRO instrument development.
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OBJECTIVES: Dysuria, xerostomia, anxiety and depression after initiation of treat-
ment with inhaled medicine have not been fully evaluated. The aim of this study
was to investigate the impact of treatment with inhaled drugs on these symptoms.
METHODS: This was a multicenter, prospective study conducted in 3 respiratory
clinics in Korea. The symptoms of dysuria, xerostomia, anxiety and depression
were observed via the International Prostate Symptoms Score (IPSS), Xerostomia
questionnaire (XQ), Hospital Anxiety & Depression Scale (HADS) at the baseline, 4
weeks, 12 weeks after initiation of inhalation therapy. The patients were divided
into two subgroups according to inhaler medication (: combination of inhaled
corticosteroids (ICS) and Long-acting 2-agonist (LABA) II: Long-acting muscarinic
antagonist (LAMA)). RESULTS: Among 90 patients enrolled, 84 patients were ana-
lyzed. After initiation of treatment with inhaled drugs, IPSS and XQ were not
changed significantly (IPSS, 11.969.85, 12.98 9.88, 13.85 0.08; XQ, 8.92 10.96,
10.31  11.33, 11.42  12.82 in the baseline, 4 weeks, 12 weeks respectively). HADS
at 12 weeks were significantly higher than that in the baseline. (p0.037) (9.61 
5.18, 10.36 6.07, 10.85  6.27 in the baseline, 4 weeks, 12 weeks respectively).
CONCLUSIONS: This study results indicate that Inhaler adversely affected dysuria,
xerostomia, anxiety and depression in new inhaler uses. But those differences
were not statistically significant except HADS. And further large sample size study
is needed.
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OBJECTIVES: 1) to identify concepts relevant to patients when measuring cognitive
symptoms of depression and their impacts, and 2) to adapt an existing patient-
reported measure of cognitive function for MDD. METHODS: Four age-stratified
focus groups (total N  33) were conducted with adults under treatment for MDD.
Following open concept elicitation, participants provided feedback on two self-
report measures of cognitive symptoms: the Applied Cognition General Concerns
Scale (Gerson et al., 2006) and the Perceived Deficits Questionnaire (PDQ) (Sullivan
et al., 1990). Focus group results led to a modified PDQ for MDD. Two sets of cogni-
tive interviews with additional MDD patients (N  17) refined the instrument,
resulting in the PDQ for Depression (PDQ-D). RESULTS: Focus group participants
reported seven different categories of cognitive symptoms. Across the age strata,
the most bothersome were difficulties with concentration, attention and memory.
Patients described many ways their cognitive symptoms affected them; productiv-
ity limitations were among the most salient. While most focus group participants
deemed the PDQ content appropriate, a shorter reference period and more explicit
response options were suggested. Cognitive interview results suggested that the
initial version of the 20-item PDQ-D was an appropriate and comprehensive as-
sessment of cognitive symptoms of MDD. Interview participants found the items
easy to understand and answer. Minor modifications made in early interviews
facilitated completion of the measure in later interviews. CONCLUSIONS: The
PDQ-D is a patient-reported assessment of cognitive function with potential to
provide unique information important for comprehensive evaluation of individual
patients with MDD and new treatments for this disorder.
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OBJECTIVES: To model the longitudinal latent effect on self-reported changes in
sleep disturbances and disability of adding pregabalin (PGB) to the usual care (UC)
therapy of outpatients with GAD treated in routine (Real World) clinical practice.
METHODS: A post-hoc analysis was performed using refractory outpatients with
GAD enrolled in a 6-month, prospective study carried-out in psychiatric clinics.
Anxiety symptoms, self-reported sleep disturbances and disability changes at end-
of-trial visit were assessed with the Hamilton-Anxiety (HAM-A), MOS-sleep and
WHO-DAS-II scales, respectively. Adding PGB to the UC was compared to UC alone
and its direct and indirect effects (expressed in percentages as the total effect
explained by the model) were estimated by means of a conditional latent curve
model applying structural equation modeling, with treatment as exogenous vari-
able, and anxiety as covariates. RESULTS: A total of 1546 (68% women, mean age;
45.5 years) PGB naïve patients were included in the analysis. Either symptoms of
anxiety, sleep disturbances or disability scores were significantly improved at end-
of-trial, with higher scores reduction in the cohort adding PGB: -15.92 vs. -14.48 in
HAM-A (F4.9, p0.027), -29.67 vs. -23.98 in MOS-sleep (F16.3, p0.001), and
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-23.78 vs. -19.71 in WHO-DAS-II (F24.5, p0.001), respectively. After discounting
the effect on anxiety reduction over time, the estimated PGB effect over UC in-
crease on both sleep disturbances and disability scores were still significant (g-
3.99, p0.001 and g-3.07, p0.001, respectively). Mediation analysis showed that
70% and 58% of the direct effect of PGB over, respectively, sleep disturbances and
disability remained after discounting the mediated effect of anxiety improvement.
CONCLUSIONS: Adding pregabalin to usual care produced better improvements in
sleep disturbances and disability related GAD symptoms in outpatients treated in
real world conditions. 70% and 58% of the total effect of PGB over usual care was
explained by its direct effect not mediated by improvements in anxiety symptoms.
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OBJECTIVES: Specific instruments are developed measuring HRQoL in children and
adolescents. Currently, these instruments are not applicable in health economic
studies as valuations for health states are lacking. The aim of the current study was
to compare the psychometric properties of a generic child-specific and a generic
preference based instrument in children and adolescents with ADHD. METHODS:
A questionnaire survey was performed among parents with a child diagnosed with
ADHD. Results on the proxy versions of the KIDSCREEN-10 and the EQ-5D were
used to compare the constructs describing HRQoL of the instruments and their
responsiveness to different health states. Principal Component Analaysis (PCA)
with varimax rotation was used for identifying factors underlying the constructs of
both instruments. A comparison was performed of the index scores on both instru-
ments between respondents with different stimulant medication profiles and dif-
ferent comorbidity profiles using Student’s t-tests. Additionally, Cohen’s effect
sizes were calculated for an indirect comparison of the instruments’ responsive-
ness and discriminating ability. RESULTS: Using the EQ-5D dimensions and the
items of the KIDSCREEN -10 the PCA identified 5 separate components of HRQoL. A
physical component and a mental component included a combination of EQ-5D
dimensions and KIDSCREEN-10 items. No associations of the EQ-5D dimensions
‘self-care’ and ‘usual activities’ and KIDSCREEN-10 items was found. Additionally,
no association was found of KIDSCREEN-10 items related to performance at school
and satisfaction with free time activities and EQ-5D dimensions. Scores of both
instruments differed significantly according to respondents’ treatment and comor-
bidity profile. Cohen’s effect sizes indicated comparable responsiveness and dis-
criminative ability of the instruments. CONCLUSIONS: The results highlight that
the two instruments measure different constructs of HRQoL. Despite this, the anal-
yses showed comparable responsiveness to different health states and discrimi-
native ability of the instruments. These results suggest that the KIDSCREEN and
the EQ-5D are complementary instruments.
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OBJECTIVES: Patient-reported outcomes (PROs) are widely used in mental health
research to assess treatment benefits for patients. The objective of this study is to
evaluate literature describing health-related quality of life (HR-QoL) PRO tools used
in schizophrenia, and to report level of validation of available instruments.
METHODS: A systematic search of the EMBASE, Pubmed and ISPOR conference
abstracts databases was conducted. No restrictions on date of submission or geo-
graphical region were applied. Conceptual framework, reliability (internal consis-
tency and reproducibility), validity (content validity and construct validity) and
sensitivity to change for the measures were evaluated. RESULTS: Fifiteen instru-
ments were identified (4 generic, 3 severe mental illness specific, 5 schizophrenia
specific and for 2 instruments it was not possible to retrieve this information).
Among generic questionnaires EQ-5D had the highest level of validity and a rea-
sonable level of sensitivity to change. Among severe mental illness specific ques-
tionnaires, The Tolerability And Quality Of Life Questionnaire (TOOL) showed high
validity, reliability and sensitivity. Subjective experience of antipsychotic drugs
was well-assessed with the Subjective Well-being under Neuroleptics Scale (SWN).
The validity of the SWN was acceptable and the tool included assessment of sub-
jective experience to evaluate differential effects of anti-psychotics and dose reg-
imens. Amongst the schizophrenia specific PROs to evaluate QoL, the quality Of
Life Questionnaire In Schizophrenia (S-QoL) was judged to have a high level of
validity and sensitivity to change and the quality of life measure for persons with
schizophrenia (QOLM-S), a 30-item scale, also showed internal reliability and con-
struct validity. CONCLUSIONS: Within schizophrenia, EQ-5D appears to have high
level of validity and sensitivity to change compared to other generic instruments.
Two disease specific instruments were considered as validated among which S-
QoL was the only one to show sensitivity to change. Our recommendation would be
to use EQ-5D or S-QoL in future studies.
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OBJECTIVES: To evaluate health-related quality of life (HRQOL) and its determi-
nants in Japanese patients with chronic schizophrenia on antipsychotic
polypharmacy. METHODS: The data were collected from an ongoing prospective
randomized comparative study entitled, “The clinical study to correct multiple and
large amount of administering to antipsychotic safely and effectively,” conducted
in Japan. The subjects were 133 Japanese patients diagnosed with schizophrenia.
Of these, 75 were evaluated once, while 49 and 9 were evaluated twice and three
times, respectively. Therefore, we were able to use data from a total of 200 evalu-
ations. The subjects’ mental status was assessed with the Manchester Scale (MS).
The severity of extrapyramidal side effects was assessed with the Drug-Induced
Extrapyramidal Symptoms Scale (DIEPSS), and the severity of autonomic side ef-
fects was assessed with the subscales extracted from the “Udvalg for Kliniske
Undersogelser(UKU).” HRQOL was evaluated using the EuroQOL (the EQ-5D and the
visual analogue scale, EQ-VAS). Independent determinants of HRQOL were identi-
fied using stepwise multiple regression analysis. RESULTS: The mean age (stan-
dard deviation) of the subjects was 56.4 (11.4). There were 54 females and 78 males.
The average disease duration was 29.2 (12.3) years. The mean utility score derived
from the EQ-5D of the total of 200 evaluations was 0.711 (0.211). The mean EQ-VAS
score was 0.632 (0.213). Independent determinants of reduced utility score were:
severity of “hallucinations” in the MS; “diarrhea” and “orthostatic dizziness” in the
UKU; severity of “gait” in the DIEPSS; and female gender.CONCLUSIONS:This is the
first report investigating the determinants of HRQOL in patients with schizophre-
nia in Japan. This report suggests that in addition to hallucinations, several side
effects induced by antipsychotics, such as diarrhea, postural hypotension, and
Parkinsonism, might play an important role in patients with schizophrenia.
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OBJECTIVES: To elicit the willingness to pay (WTP) of different stakeholders re-
garding different aspects of treatment of schizophrenia.METHODS:We conducted
a survey of 259 Swedes with a serious mental disorder, 263 relatives of individuals
suffering from a serious mental disorder and 528 people sampled from the general
population. We designed a discrete choice experiment (DCE) to determine respon-
dents’ WTP. Conditional logit was used to derive the WTP results. RESULTS: The
value of reducing the required frequency from every other week to once a month is
141 SEK per month for patients, 192 SEK per month for relatives, and 227 SEK per
month for the general population. The value of reducing the required frequency
from every other week to once every 3 months is 269 SEK per month for patients, 349
SEK per month for relatives, and 414 SEK per month for the general population.
Accompanying visits every 3 months with a consultation about general well-being
is worth 149 SEK per month for patients, 247 SEK per month for relatives, and 148
SEK per month for the general population. The value of being able to store medi-
cation outside a refrigerator at room temperature instead of in a refrigerator is 130
SEK per month for patients, 176 SEK per month for relatives, and 198 SEK per month
for the general population. CONCLUSIONS: There is a significant, positive willing-
ness to pay for reduced injection frequency (at doctors’ or cliniques), not having to
store drugs in refrigerator compared to storage at room temperature, and having
consultation about general well-being every three months.
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OBJECTIVES: Stigma and prejudice surrounding people with mental illnesses are a
major impediment that contributes to prevent them to access to health care. This
is the first part of a project that aims to assess impact of mental disorders stigma on
willingness to pay for health care. The first part of the project describes public
beliefs and attitudes about schizophrenia, major depression and psychotropic
drugs. METHODS: Three questionnaires were administered online to a represen-
tative sample of 2400 French people. 800 persons answered a questionnaire on
schizophrenia, 800 on major depression and 800 about psychotropic drugs. They
were asked to address a validated questionnaire. RESULTS:All 2400 questionnaires
were fully completed. 57.9% (resp. 35.3%) of people reported being not comfortable
in presence of a schizophrenic patient (resp. major depression), while 18.6% (resp.
39.0%) reported they did. More than 72.1% (resp. 80.9%) felt the need to help people
suffering from schizophrenia (resp. major depression), although 60.0% (resp. 16.3%)
think that such patients are strange, and 36.1% (resp. 14.5%) think they are danger-
ous. 9.1% agree with the fact that psychotropic treatment helps people to better
support the concerns of everyday life and 8.8% agree with taking these medicines
if the person suffers constantly of light mood swings. CONCLUSIONS: This study
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